Takara Holdings slashes full-year profit outlook amid sales slowdown

Takara Holdings reported a 5.7% year-on-year increase in net sales to 186,556 million yen for the six months ended September 30, 2025. However, operating income decreased by 26.1% to 7,786 million yen, and ordinary income fell by 33.9% to 7,386 million yen. Net income attributable to owners of the parent also saw a significant decline of 37.3% to 5,695 million yen.

The company's total assets stood at 476,611 million yen, a slight decrease from 477,587 million yen at the end of March 2025. Total liabilities increased by 12,470 million yen to 189,154 million yen, while total net assets decreased to 287,456 million yen, resulting in an equity ratio of 49.8%. The Takara Bio Group recorded an impairment loss of 3,870 million yen and an increase in goodwill of 6,337 million yen due to the acquisition of Curio Bioscience, Inc.

The full-year consolidated forecast for the fiscal year ending March 31, 2026, has been revised. Net sales are now projected at 392,000 million yen, down 2.2% from the previous forecast of 401,000 million yen. Operating income is expected to be 16,200 million yen, a 26.0% decrease, and ordinary income is forecast at 15,700 million yen, down 29.3%. Net income attributable to owners of the parent is projected to be 11,100 million yen, a 31.5% decrease from the earlier forecast.